UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
July 21, 2004
Date of Report (date of Earliest Event Reported)
ISOLAGEN, INC.
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE |
|
001-31564 |
|
87-0458888 |
|
(State or Other Jurisdiction of |
|
(Commission File No.) |
|
(I.R.S. Employer Identification No.) |
2500 Wilcrest, 5th Floor, Houston, Texas 77042
(Address of principal executive offices and zip code)
(713) 780-4754
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Item 5. Other Events.
On July 21, 2004, the Company issued a press release announcing the commencement of its Phase III Pivotal Trials. The reader is advised to read the press release in its entirety.
[THE SIGNATURE PAGE FOLLOWS.]
2
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ISOLAGEN, INC. |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: July 21, 2004 |
|
By: |
/s/ Jeffrey W. Tomz |
|
|
|
|
|
Chief Financial Officer |
|
3